<h1>Pharma Company Reports Q1 FY26 Profit Surge, Boosted by Efficiency and Strategic Growth Plans &DExpansion</h1> A pharmaceutical company reported a significant financial turnaround in the first quarter of fiscal year 2026, achieving a profit after tax (PAT) of 464.88 lakhs, reversing a prior quarter loss and surpassing the entire previous fiscal year's PAT of 212.94 lakhs. The company attributed this improvement to enhanced operational efficiency, cost management, and strategic execution. It posted revenue from operations of 11,336.67 lakhs and a profit before tax of 571.23 lakhs. The company plans to expand its research and development efforts in key therapeutic areas, strengthen its contract development and manufacturing services, and pursue global market expansion. These initiatives aim to drive innovation, improve margins through backward integration, and enhance supply chain management. The company's robust quarterly performance positions it for sustained growth and consolidation of its market leadership domestically and internationally.